Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECIR sugammadex dose study in elderly patients undergoing robot-assisted prostatectomy
2020-004704-34Phase 3Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sugammadex in prostate cancer (PCa) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Neuromuscular recovery time. Started May 2021; status: completed.
02
Drugs
Sugammadex
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-004704-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004704-34.